Nanotop (Human Serum Albumin)

Human Serum Albumin acts as a colloidal osmotic agent. When infused, it raises the concentration of albumin in the bloodstream, which draws water from the interstitial spaces into the vascular compartment, thereby expanding blood volume and improving oncotic pressure.

The dose of Nanotop is determined by the prescribing clinician based on the patient’s clinical condition, serum albumin level, and volume status. Dosing is individualized and should follow the prescriber’s specific instructions.

Safety data for Human Serum Albumin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nanotop, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Nanotop (Human Serum Albumin) provides oncotic pressure similar to natural plasma proteins, unlike crystalloids which act primarily through hydrostatic pressure. Compared with synthetic colloids, albumin has a lower risk of coagulopathy and renal impairment, making it a preferred choice in certain clinical scenarios.

Nanotop must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the product appears discolored or contains particles.

Nanotop is administered by intravenous or subcutaneous injection under aseptic conditions. The infusion rate and volume are set by the healthcare professional according to the patient’s needs and monitoring parameters.

Serious risks include anaphylactic reactions, pulmonary edema from fluid overload, acute hemolysis, and rare transmission of infectious agents. Prompt recognition and management of these events are essential.

Nanotop should be avoided in patients with known hypersensitivity to Human Serum Albumin or any component of the formulation, in those with uncontrolled heart failure where fluid overload is a concern, and in individuals where the risk of volume expansion outweighs the clinical benefit.